Icon

CYTARABINE (nda016793)- (1GM/VIAL,2GM/VIAL,100MG/VIAL,500MG/VIAL)

CYTARABINE TEVA PARENTERAL
1GM/VIAL,2GM/VIAL,100MG/VIAL,500MG/VIAL
No No
Expired Expired
None None
None No
Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute non-lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
9 0 5
Total Other Developers 6
Drugs with Suitability Yes
1GM/VIAL ** ** - - -
2GM/VIAL ** ** - - -
100MG/VIAL ** ** - - -
500MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ******* ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** ******** ****** *************** **., ***. *********** **.*-* ***** ****, ******* **-**** ************* ****** ****, *******, ******* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.